More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod

 
• By Lucie Ellis-Taitt

NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.

Juggling
NewLink juggles too many indoximod options; drops pancreatic cancer program • Source: Shutterstock

More from Immuno-oncology

More from Anticancer